| Description |
Astodrimer (SPL7013 free base) is a large (3-4 nm, ~ 16.5 kDa), negatively charged, highly-branched dendrimer, is a potent virucidal agent. Astodrimer shows antiviral and virucidal activity against a broad spectrum of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, HPV. Astodrimer also has antibacterial properties[1][2][3].
|
| Related Catalog |
|
| In Vitro |
Astodrimer (0-10 mg/mL; 4 days) inhibits SARS-CoV-2 (hCoV-19/Australia/VIC01/2020) replication against SARS-CoV-2 (hCoV-19/Australia/VIC01/2020) infection of Vero E6 cells[1]. Astodrimer inhibits the 2019-nCoV/USA-WA1/2020 strain with EC50 values of 0.019–0.032 mg/mL and 0.030–0.037 mg/mL for infectious virus in Vero E6 cell and Calu-3 cells, respectively[1]. Cell Proliferation Assay[1] Cell Line: Vero E6 cells Concentration: 0-10 mg/mL(1 h prior to infection, or 1 h post-infection with SARS-CoV-2) Incubation Time: 4 days Result: Inhibited viral replication when added either 1 h prior to infection, or 1 h post-infection with SARS-CoV-2 in a dose dependent manner.
|
| In Vivo |
Astodrimer (3%, 8 times daily for 4 days then 4 times daily for 6 days) is non-toxic to rabbit eyes and has anti-adenoviral activity in NZW rabbits[2]. Astodrimer (1%, intranasal administration; once daily for 5 days) reduces the severity of SARS-CoV-2 replication and pathogenesis in the highly susceptible K18-hACE2 mouse model[3]. Animal Model: Two- to three-pound female NZW rabbits (both eyes with HAdV5 following corneal scarification)[2]. Dosage: 3% SPL7013 Administration: 8 times daily for 4 days then 4 times daily for 6 days Result: Inactivated the virus, and the resulting reduction in the exposure to the virus in vivo limits SARS-CoV-2 infection, resulting in significantly lower viral loads and infectious virus in the lung, trachea, brain and liver of K18-hACE2 mic, and significantly lower pro-inflammatory cytokine production. Animal Model: Six-to-eight-week-old K18-hACE2 mice[3] Dosage: 1% astodrimer sodium nasal spray Administration: Intranasal administration; 25 µL/nostril; once daily on Days 1-6. Result: Significantly reduced the severity of SARS-CoV-2 replication and pathogenesis in the highly susceptible K18-hACE2 mouse model.
|
